Glenmark Pharma
- All
- News
- Videos
-
Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million
Drugmaker Glenmark Pharmaceuticals said on Thursday it would sell a 75% stake in unit Glenmark Life Sciences to detergent maker Nirma for 56.52 billion rupees ($679.84 million).
-
Glenmark Pharmaceuticals Recalls 1,200 Bottles Of "Subpotent" Hypertension Drug In US
Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
First Nasal Spray For Treating Adult Covid Patients Launched In India
Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.
-
Stocks To Watch: ONGC, Glenmark Pharma, Apollo Hospitals, SpiceJet
ONGC reported a decline in net profit to Rs 4,334.8 crore in the quarter ended June 2021 from Rs 6,734 crore in the same quarter last year
-
Glenmark Life Sciences IPO Subscribed Nearly 45 Times On Final Day Of Issue
Glenmark Life Sciences' share sale via initial public offering (IPO) was subscribed by 44.17 times on Thursday, July 29- the third and final day of its issue.
-
Stocks To Watch: HDFC Bank, Macrotech Developers, Glenmark Pharma
HDFC Bank reported net profit of Rs 8,186.51 crore in the January-March quarter, an increase of 18.2 per cent compared to Rs 6,927.69 crore during the same period last year
-
Volume Decline Muted Pharmaceutical Market Growth In November
The pharmaceutical market reported 128.3 billion total sales in November 2020 and decline in volume can be attributed to the lower sales of the acute therapy products
-
Glenmark Pharma Gets Regulatory Nod For Tacrolimus Capsules; Stock Gains Nearly 2%
Glenmark Pharma received final approval from USFDA for Tacrolimus capsules, which are used as immunosuppressants to prevent human immune system from rejecting liver, kidney and heart transplants.
-
Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version
Glenmark denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.
-
Glenmark Shares Surge Over 35% On Regulatory Approval For COVID-19 Drug
Favipiravir being manufactured by Glenmark will be marketed by the name of Fabiflu and will be available in strength of 200 milligrams.
-
Glenmark Gets Approval For Favipiravir As COVID-19 Treatment
Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014.
-
Sun Pharma To Test Pancreatitis Drug In COVID-19 Patients
The company joins other drugmakers Glenmark and Strides Pharma Science that are conducting trials in India for potential drugs for COVID-19.
-
Glenmark To Conduct Clinical Trials For Potential COVID-19 Drug; Shares Surge
Glemark said the approval made it the first pharmaceutical company in India to be given the go-ahead to start trials on COVID-19 patients.
-
Glenmark Pharma To Conduct Trials For Potential COVID-19 Drug, Shares Jump
Glenmark Pharmaceuticals, which rose as much as 8.9 per cent to Rs 359, traded up 5.9 per cent at 9:37 am.
-
Glenmark Pharma To Sell 75% Stake In Life Sciences To Nirma For $680 Million
Drugmaker Glenmark Pharmaceuticals said on Thursday it would sell a 75% stake in unit Glenmark Life Sciences to detergent maker Nirma for 56.52 billion rupees ($679.84 million).
-
Glenmark Pharmaceuticals Recalls 1,200 Bottles Of "Subpotent" Hypertension Drug In US
Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).
-
Glenmark Pharmaceuticals Gets Final US Approval For Lacosamide Tablet
Homegrown pharma major Glenmark Pharmaceuticals Ltd on Monday said it has received final approval from the US health regulator for its generic Lacosamide tablet, indicated for prevention and control of seizures.
-
First Nasal Spray For Treating Adult Covid Patients Launched In India
Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.
-
Stocks To Watch: ONGC, Glenmark Pharma, Apollo Hospitals, SpiceJet
ONGC reported a decline in net profit to Rs 4,334.8 crore in the quarter ended June 2021 from Rs 6,734 crore in the same quarter last year
-
Glenmark Life Sciences IPO Subscribed Nearly 45 Times On Final Day Of Issue
Glenmark Life Sciences' share sale via initial public offering (IPO) was subscribed by 44.17 times on Thursday, July 29- the third and final day of its issue.
-
Stocks To Watch: HDFC Bank, Macrotech Developers, Glenmark Pharma
HDFC Bank reported net profit of Rs 8,186.51 crore in the January-March quarter, an increase of 18.2 per cent compared to Rs 6,927.69 crore during the same period last year
-
Volume Decline Muted Pharmaceutical Market Growth In November
The pharmaceutical market reported 128.3 billion total sales in November 2020 and decline in volume can be attributed to the lower sales of the acute therapy products
-
Glenmark Pharma Gets Regulatory Nod For Tacrolimus Capsules; Stock Gains Nearly 2%
Glenmark Pharma received final approval from USFDA for Tacrolimus capsules, which are used as immunosuppressants to prevent human immune system from rejecting liver, kidney and heart transplants.
-
Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version
Glenmark denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.
-
Glenmark Shares Surge Over 35% On Regulatory Approval For COVID-19 Drug
Favipiravir being manufactured by Glenmark will be marketed by the name of Fabiflu and will be available in strength of 200 milligrams.
-
Glenmark Gets Approval For Favipiravir As COVID-19 Treatment
Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014.
-
Sun Pharma To Test Pancreatitis Drug In COVID-19 Patients
The company joins other drugmakers Glenmark and Strides Pharma Science that are conducting trials in India for potential drugs for COVID-19.
-
Glenmark To Conduct Clinical Trials For Potential COVID-19 Drug; Shares Surge
Glemark said the approval made it the first pharmaceutical company in India to be given the go-ahead to start trials on COVID-19 patients.
-
Glenmark Pharma To Conduct Trials For Potential COVID-19 Drug, Shares Jump
Glenmark Pharmaceuticals, which rose as much as 8.9 per cent to Rs 359, traded up 5.9 per cent at 9:37 am.
